UPDATE: Wedbush Securities Initiates Coronado Biosciences at Outperform on Outlook for CNDO-201
Wedbush Securities initiated coverage on Coronado Biosciences (NASDAQ: CNDO) with an Outperform rating and a $13 price target.
Wedbush Securities commented, "We believe that CNDO-201 is likely to find substantial use in the 40% of patients with inflammatory bowel disease (IBD) that fail last-line TNF-alpha therapy. Moreover, given the drawbacks and growing concerns about the safety of TNF-alpha's and corticosteroids, we believe that CNDO-201, driven by superior safety and tolerability, could displace TNF-alpha therapies and be used in combination with current first-line therapies in IBD, a market worth >$4 billion."
Coronado Biosciences closed at $4.79 on Wednesday.
Latest Ratings for CNDO
|Mar 2015||MLV & Co.||Upgrades||Hold||Buy|
|Nov 2013||Bank of America||Downgrades||Neutral||Underperform|
|Oct 2013||MLV & Co.||Downgrades||Buy||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.